Cart
sales@molnova.com
alpha-Amyrin palmitate
CAS No. 22255-10-3
alpha-Amyrin palmitate( ——— )
Catalog No. M39388 CAS No. 22255-10-3
α-Amyrin palmitate is isolated from Santalum album (sandalwood). α-Amyrin palmitate can be used for the study of arthritis in vivo.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 225 | In Stock |
|
| 25MG | Get Quote | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namealpha-Amyrin palmitate
-
NoteResearch use only, not for human use.
-
Brief Descriptionα-Amyrin palmitate is isolated from Santalum album (sandalwood). α-Amyrin palmitate can be used for the study of arthritis in vivo.
-
Descriptionalpha-Amyrin palmitate is antiarthritic in the adjuvant model of arthritis in rats. alpha-Amyrin palmitate is a potent non-competitive inhibitor of chymotrypsin (Ki=6 microM), it also shows weak cytotoxicity against the A2780 human ovarian cancer cell line.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayApoptosis
-
TargetPKA
-
RecptorPKA
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number22255-10-3
-
Formula Weight665.13
-
Molecular FormulaC46H80O2
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. G Kweifio-Okai, et al. Effect of Alpha-Amyrin Palmitate on Adjuvant Arthritis. Drugs Exp Clin Res.?1994;20(1):1-5.?
molnova catalog
related products
-
Hydroxyfasudil
Hydroxyfasudil is a ROCK inhibitor(IC50s of 0.73 and 0.72 μM for ROCK1 and ROCK2, respectively).
-
Calcineurin substrat...
Calcineurin Substrate is a Peptide from the regulatory RII subunit of cAMP-dependent protein kinase.
-
Synaptamide
An endogenous DHA metabolite that promotes neurite growth, synaptogenesis, and synaptic function both in vitro and in vivo.
